Sanae Yasuda

1.1k total citations
40 papers, 938 citations indexed

About

Sanae Yasuda is a scholar working on Molecular Biology, Physiology and Oncology. According to data from OpenAlex, Sanae Yasuda has authored 40 papers receiving a total of 938 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 7 papers in Physiology and 6 papers in Oncology. Recurrent topics in Sanae Yasuda's work include Pharmacogenetics and Drug Metabolism (5 papers), Alzheimer's disease research and treatments (5 papers) and Gastroesophageal reflux and treatments (4 papers). Sanae Yasuda is often cited by papers focused on Pharmacogenetics and Drug Metabolism (5 papers), Alzheimer's disease research and treatments (5 papers) and Gastroesophageal reflux and treatments (4 papers). Sanae Yasuda collaborates with scholars based in Japan, United States and United Kingdom. Sanae Yasuda's co-authors include D M Chuang, Zoya Marinova, Chiyuki Yamato, Yukio Horai, Takashi Ishizaki, Kan Chiba, Yoshiro Tomono, Kaoru Kobayashi, Yuzo Tomono and Masanori Kayano and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

Sanae Yasuda

36 papers receiving 903 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sanae Yasuda Japan 14 241 191 186 132 121 40 938
Jeremy D. Gale United States 23 290 1.2× 320 1.7× 349 1.9× 246 1.9× 80 0.7× 51 1.4k
Pamela L. Golden United States 14 269 1.1× 117 0.6× 133 0.7× 63 0.5× 70 0.6× 28 1.2k
Cristiana Stefan Canada 22 734 3.0× 103 0.5× 97 0.5× 77 0.6× 102 0.8× 48 1.9k
Antonia Periclou United States 17 183 0.8× 73 0.4× 38 0.2× 125 0.9× 395 3.3× 36 1.2k
Shigeru Furuta Japan 15 113 0.5× 98 0.5× 53 0.3× 135 1.0× 25 0.2× 71 771
Wendy Luo United States 16 262 1.1× 68 0.4× 63 0.3× 60 0.5× 72 0.6× 34 823
R Stoltz United States 19 337 1.4× 129 0.7× 15 0.1× 145 1.1× 159 1.3× 31 1.2k
Jo Mori Japan 17 346 1.4× 75 0.4× 48 0.3× 210 1.6× 60 0.5× 66 945
J.P. Long United States 19 625 2.6× 135 0.7× 33 0.2× 359 2.7× 55 0.5× 123 1.4k
Alan Kosaka United States 16 544 2.3× 51 0.3× 25 0.1× 281 2.1× 56 0.5× 26 1.5k

Countries citing papers authored by Sanae Yasuda

Since Specialization
Citations

This map shows the geographic impact of Sanae Yasuda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sanae Yasuda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sanae Yasuda more than expected).

Fields of papers citing papers by Sanae Yasuda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sanae Yasuda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sanae Yasuda. The network helps show where Sanae Yasuda may publish in the future.

Co-authorship network of co-authors of Sanae Yasuda

This figure shows the co-authorship network connecting the top 25 collaborators of Sanae Yasuda. A scholar is included among the top collaborators of Sanae Yasuda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sanae Yasuda. Sanae Yasuda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hayato, Seiichi, Lora Hamuro, Toshio Shimizu, et al.. (2025). Pharmacokinetic and Exposure–Response Modeling Support Body Surface Area‐Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors. The Journal of Clinical Pharmacology. 65(6). 751–762. 1 indexed citations
2.
Hasunuma, Tomoko, et al.. (2024). Effects of Food, Gastric Acid Reduction, and Strong CYP3A Induction on the Pharmacokinetics of Tasurgratinib, a Novel Selective Fibroblast Growth Factor Receptor Inhibitor. The Journal of Clinical Pharmacology. 64(12). 1541–1551. 1 indexed citations
3.
Majid, Oneeb, Youfang Cao, Brian A. Willis, et al.. (2024). Population pharmacokinetics and exposure–response analyses of safety (ARIA‐E and isolated ARIA‐H) of lecanemab in subjects with early Alzheimer's disease. CPT Pharmacometrics & Systems Pharmacology. 13(12). 2111–2123. 6 indexed citations
4.
5.
Geerts, Hugo, Piet H. van der Graaf, Edgar Schuck, et al.. (2023). A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease. CPT Pharmacometrics & Systems Pharmacology. 12(4). 444–461. 13 indexed citations
6.
Yasuda, Sanae, et al.. (2023). A Single- and Multiple-Dose Pharmacokinetic Study of Oral Perampanel in Healthy Chinese Subjects. Clinical Drug Investigation. 43(3). 155–165. 6 indexed citations
7.
Willis, Brian A., Ziad Hussein, Seiichi Hayato, et al.. (2023). Exposure‐response modeling to describe the change in brain amyloid following lecanemab administration in patients with early Alzheimer’s disease. Alzheimer s & Dementia. 19(S21). 1 indexed citations
8.
Sekino, Hisakuni, et al.. (2020). Bioequivalence of perampanel fine granules and tablets in healthy Japanese subjects. International Journal of Clinical Pharmacology and Therapeutics. 58(12). 757–764. 4 indexed citations
9.
Nakai, Kenya, Sanae Yasuda, Mark Matijevic, et al.. (2018). Safety, pharmacokinetics, and pharmacodynamics in first-in-human study of a novel compound E6742, a Toll-like receptor 7 and 8 antagonist. Proceedings for Annual Meeting of The Japanese Pharmacological Society. WCP2018(0). PO1–11. 3 indexed citations
10.
Yasuda, Sanae, et al.. (2007). The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Molecular Psychiatry. 14(1). 51–59. 289 indexed citations
11.
Yasuda, Sanae, Atsunori Kaibara, Ryosei Kawai, et al.. (2005). A Point of Consider on Credible and Efficient Dose Selection Based on the Exposure-Response Relationship. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 36(5). 247–253.
12.
Yamada, Yasuhide, Noboru Yamamoto, Tatsu Shimoyama, et al.. (2005). Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days. Cancer Science. 96(10). 721–728. 26 indexed citations
13.
Okada, Masato, et al.. (2002). Differential Display of Protein Tyrosine Kinase cDNAs from Human Fetal and Adult Brains. BioTechniques. 32(4). 856–865. 1 indexed citations
14.
Ogasawara, Kuniaki, Sanae Yasuda, Toru Beppu, et al.. (2001). Brain PET and technetium-99m-ECD SPECT imaging in Lhermitte-Duclos disease. Neuroradiology. 43(11). 993–996. 11 indexed citations
15.
Shimoda, Kazutaka, et al.. (1999). Pronounced Differences in the Disposition of Clomipramine Between Japanese and Swedish Patients. Journal of Clinical Psychopharmacology. 19(5). 393–400. 20 indexed citations
16.
Yasuda, Sanae, et al.. (1995). Stereoselective inhibition of CYP2D6 by chlorpheniramine. Clinical Pharmacology & Therapeutics. 57(2). 149. 6 indexed citations
17.
Ito, Isao, Masataka Yoshimoto, Takuji Iwase, et al.. (1995). Association of genetic alterations on chromosome 17 and loss of hormone receptors in breast cancer. British Journal of Cancer. 71(3). 438–441. 48 indexed citations
18.
Yasuda, Sanae, Yukio Horai, Yoshiro Tomono, et al.. (1995). Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clinical Pharmacology & Therapeutics. 58(2). 143–154. 121 indexed citations
19.
Hirama, Masahiro, Takeshi Noda, Sanae Yasuda, & Shô Itô. (1991). ChemInform Abstract: Simple Strategy for the Synthesis of the Avermectin‐Milbemycin Family. Total Synthesis of Milbemycin α1.. ChemInform. 22(24). 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeremy D. Gale Breakdown of academic impact, for papers by Pamela L. Golden Breakdown of academic impact, for papers by Cristiana Stefan Breakdown of academic impact, for papers by Antonia Periclou Breakdown of academic impact, for papers by Shigeru Furuta Breakdown of academic impact, for papers by Wendy Luo Breakdown of academic impact, for papers by R Stoltz Breakdown of academic impact, for papers by Jo Mori Breakdown of academic impact, for papers by J.P. Long Breakdown of academic impact, for papers by Alan Kosaka
Rankless by CCL
2026